Xbrane Biopharma AB (publ) (OM: XBRANE)
Health Care · Biotechnology · SE
Skr9.36
-1.47% today · -73.9% 1Y
Xbrane Biopharma AB (publ) (OM: XBRANE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $20.67M and employs 29 people.
Over the last twelve months the share price has lost 73.9%, trading between 5.42 and 37.65.
Tweenvest scores Xbrane Biopharma AB (publ) across four factors: quality 23/100, value 53/100. Its strongest factor is value.
XBRANE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $20.67M
- Revenue (TTM)
- $8.59M
- P/E
- —
- EPS
- -3.95
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- Skr37.65
- 52-week low
- Skr5.42
- Avg volume (3M)
- —
- Shares outstanding
- 20.61M
- Employees
- 29
- Next earnings
- —
About Xbrane Biopharma AB (publ)
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
- ISIN
- SE0026598583
- Founded
- 2008
- Listed since
- Feb 3, 2016
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.82 | +0.39% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $445.50 | +0.74% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.01 | -0.52% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.